Patents by Inventor Wenhu Huang
Wenhu Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8227661Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO227, PRO233, PRO238, PRO1328, PRO4342, PRO7423, PRO10096, PRO21384, PRO353 or PRO1885 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.Type: GrantFiled: October 19, 2010Date of Patent: July 24, 2012Assignee: Lexicon Genetics, Inc.Inventors: Joel A. Edwards, Wenhu Huang, Charles Montgomery, Ni Nancy Qian, Zheng-Zheng Shi, Mary Jean Sparks, Peter Vogel, Mindy Oox
-
Publication number: 20120174239Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO224, PRO9783, PRO1108, PRO34000, PRO240, PRO943, hu A33, PRO230, PRO178, PRO1199, PRO4333, PRO1336, PRO19598, PRO1083, hu TRPM2 or PRO1801 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.Type: ApplicationFiled: October 27, 2011Publication date: July 5, 2012Inventors: Stephen Jay Anderson, Jane Brennan, Frederic J. de Sauvage, Zhiyong Ding, Joel Edwards, Nelda A. Fikes, Wenhu Huang, Wenjun Ouyang, Carolina Rangel, Mamta Sangha, Zheng-Zheng Shi, Mary Jean Sparks, Joseph Trackey, Melissa Vetter, Ching-Yun Wang, Jessica Woodings
-
Patent number: 8067664Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO224, PRO9783, PRO1108, PRO34000, PRO240, PRO943, hu A33, PRO230, PRO178, PRO1199, PRO4333, PRO1336, PRO19598, PRO1083, hu TRPM2 or PRO1801 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.Type: GrantFiled: December 13, 2004Date of Patent: November 29, 2011Assignee: Genentech, Inc.Inventor: Wenhu Huang
-
Publication number: 20110191865Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO227, PRO233, PRO238, PRO1328, PRO4342, PRO7423, PRO10096, PRO21384, PRO353 or PRO1885 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.Type: ApplicationFiled: June 3, 2009Publication date: August 4, 2011Applicants: Genentech, Inc., Lexicon Genetics IncorporatedInventors: Joel A. Edwards, Wenhu Huang, Charles A. Montgomery, Ni Nancy Qian, Zheng-Zheng Shi, Mary Jean Sparks, Peter Vogel, Mindy Westbrook
-
Publication number: 20110097330Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO179, PRO181, PRO244, PRO247, PRO269, PRO293, PRO298, PRO339, PRO341, PRO347, PRO531, PRO537, PRO718, PRO773, PRO860, PRO871, PRO872, PRO813, PRO828, PRO1100, PRO1114, PRO115, PRO1126, PRO1133, PRO1154, PRO1185, PRO1194, PRO1287, PRO1291, PRO1293, PRO1310, PRO1312, PRO1335, PRO1339, PRO2155, PRO1356, PRO1385, PRO1412, PRO1487, PRO1758, PRO1779, PRO1785, PRO1889, PRO90318, PRO3434, PRO3579, PRO4322, PRO4343, PRO4347, PRO4403, PRO4976, PRO260, PRO6014, PRO6027, PRO6181, PRO6714, PRO9922, PRO7179, PRO7476, PRO9824, PRO19814, PRO19836, PRO20088, PRO70789, PRO50298, PRO51592, PRO1757, PRO4421, PRO9903, PRO1106, PRO1411, PRO1486, PRO1565, PRO4399 or PRO4404 genes.Type: ApplicationFiled: February 27, 2006Publication date: April 28, 2011Applicants: Genentech, Inc., Lexicon Pharmaceuticals, Inc.Inventors: Allison Anne Byers Horner, Catherine Batac Clarke, Katherin E. Combs, Frederic J. de Sauvage, Joel Edwards, Paul Godowski, Deanna Grant Wilson, Wenhu Huang, Lorelei Diane Ketcherside, Erin Marie Massey, Charles Montgomery, Bobby Joe Payne, Andrew Peterson, Ni Nancy Qian, Jeffrey J. Schrick, Zheng-Zheng Shi, Mary Jean Sparks, Joy Anne Stala, Colleen M. Viator, Peter Vogel, Weilan Ye, Jung-Hua Yeh, Zhiyong Ding
-
Publication number: 20110093960Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO227, PRO233, PRO238, PRO1328, PRO4342, PRO7423, PRO10096, PRO21384, PRO353 or PRO1885 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.Type: ApplicationFiled: October 19, 2010Publication date: April 21, 2011Inventors: Joel A. Edwards, Wenhu Huang, Charles Montgomery, Ni Nancy Qian, Zheng-Zheng Shi, Mary Jean Sparks, Peter Vogel, Mindy Oox
-
Publication number: 20100031378Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO227, PRO233, PRO238, PRO1328, PRO4342, PRO7423, PRO10096, PRO21384, PRO353 or PRO1885 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.Type: ApplicationFiled: August 4, 2008Publication date: February 4, 2010Inventors: Joel A. Edwards, Wenhu Huang, Charles Montgomery, Ni Nancy Qian, Zheng-Zheng Shi, Mary Jean Sparks, Peter Vogel, Mindy Oox
-
Patent number: 7402730Abstract: Genetically engineered cells and animals are described that incorporate a mutated GHP1 allele. Animals that are homozygous for the mutated GHP1 allele are useful for the production of monoclonal antibodies against GHP1.Type: GrantFiled: February 3, 2006Date of Patent: July 22, 2008Assignee: Lexicon Pharmaceuticals, Inc.Inventors: Mary Jean Sparks, Wenhu Huang
-
Publication number: 20080160034Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO196, PRO217, PRO231, PRO236, PRO245, PRO246, PRO258, PRO287, PRO328, PRO344, PRO357, PRO526, PRO724, PRO731, PRO732, PRO1003, PRO1104, PRO1151, PRO1244, PRO1298, PRO1313, PRO1570, PRO1886, PRO1891, PRO4409, PRO5725, PRO5994, PRO6097, PRO7425, PRO10102, PRO10282, PRO61709 or PRO779 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.Type: ApplicationFiled: August 23, 2005Publication date: July 3, 2008Applicant: Genentech, Inc.Inventors: Jane Brennan, Frederic J. de Sauvage, Weilan Ye, Joel A. Edwards, Wenhu Huang, Charles Montgomery, Bobby Joe Payne, Zheng-Zheng Shi, Mary Jean Sparks, Peter Vogel
-
Publication number: 20070292438Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO224, PRO9783, PRO1108, PRO34000, PRO240, PRO943, hu A33, PRO230, PRO178, PRO1199, PRO4333, PRO1336, PRO19598, PRO1083, hu TRPM2 or PRO1801 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.Type: ApplicationFiled: December 13, 2004Publication date: December 20, 2007Inventors: Stephen Anderson, Jane Brennan, Frederic de Sauvage, Zhiyong Ding, Joel Edwards, Nelda Fikes, Wenhu Huang, Wenjun Ouyang, Carolina Rangel, Mamta Sangha, Zheng-Zheng Shi, Mary Sparks, Joseph Trackey, Melissa Vetter, Ching-Yun Wang, Jessica Woodings